MySize receives Nasdaq bid price deficiency notice; reports preliminary 2025 revenue ~$10M

My Size, Inc.

Nasdaq notified MySize on March 2, 2026 that its common stock bid price closed below $1.00 for 30 consecutive days; 180-day cure period until August 31, 2026.
Preliminary 2025 revenue approximately $10 million; Orgad segment operated at ~40% gross margins.
10peaks subsidiary generated ~$150k revenue at ~65% gross margins in 2025; management estimates potential annual revenue of ~$3M.
Company intends to regain compliance through business execution; stock continues trading on Nasdaq under MYSZ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.